Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
Inventors
Weinschenk, Toni • FRITSCHE, Jens • Singh, Harpreet • MAHR, Andrea • OTT, Martina • Wagner, Claudia • Schoor, Oliver
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12295995-B2
Publication Date
2025-05-13
Expiration Date
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Core Innovation
The invention relates to a cancer immunotherapy platform based on tumor-associated T-cell peptide epitopes. It uses tumor-associated T-cell epitopes derived from HLA class I and elongated class II-binding variants, including HLA-A*02-restricted epitopes and additional class II binding peptide variants. The document provides peptide sequence sets with specific gene origins and identifies peptides in Tables 1-2 as lacking prior cancer association.
The document reports mass spectrometry and HLA ligand identification showing natural presentation of the provided peptides on primary pancreatic cancer samples. The presented peptide set includes additional peptides for combination and/or personalized therapy, and the platform is framed to support generation of immune recognition using naturally presented peptide epitopes rather than solely theoretical or previously unobserved ligands.
The platform also supports applications extending beyond peptide administration, including vaccines and use as components for generating antibodies or soluble TCRs specific to peptide-MHC. In addition, the document articulates a broad diagnostic/prognostic concept of peptide over-presentation and gene over-expression defining biomarkers/targets. The described therapeutic indications are broad across cancer types, with emphasis on pancreatic cancer.
Claims Coverage
The independent claim coverage centers on an isolated peptide with the amino acid sequence YLYDSETKNA (SEQ ID NO: 65) provided as a salt form. Across the dependent coverage mentioned, the claims further specify pharmaceutically acceptable salt variants and related pharmaceutical composition and adjuvant formulations.
Isolated peptide comprising YLYDSETKNA as a pharmaceutically acceptable salt
An isolated peptide consisting of the amino acid sequence YLYDSETKNA (SEQ ID NO: 65) in the form of a pharmaceutically acceptable salt.
Isolated peptide comprising YLYDSETKNA as a salt
An isolated peptide consisting of the amino acid sequence YLYDSETKNA (SEQ ID NO: 65) in the form of a salt.
Chloride salt form
The peptide is provided as a pharmaceutically acceptable chloride salt.
Acetate salt form
The peptide is specified to be in the form of a pharmaceutically acceptable acetate salt.
Production by solid-phase peptide synthesis or yeast/bacterial expression
A peptide, formulated as a pharmaceutically acceptable salt, is characterized as being produced either by solid-phase peptide synthesis or via expression in a yeast or bacterial cell system.
Pharmaceutical composition with water and buffer
A pharmaceutical composition includes the peptide of claim 1, along with water and a buffer.
Adjuvant selection from specified immunotherapy/biologic group
The pharmaceutical composition includes an adjuvant selected from a specified group of immunotherapy and biologic compounds and formulation materials.
The claim coverage is centered on the specific peptide YLYDSETKNA (SEQ ID NO: 65) provided as a salt, including pharmaceutically acceptable chloride and acetate salts. It further covers related pharmaceutical compositions with water and buffer, alternative production approaches, and optional inclusion of an adjuvant chosen from a listed immunotherapy/biologic and formulation materials group.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Vaccine use for cancer immunotherapy using tumor-associated T-cell peptide epitopes.
Components for generating antibodies specific to peptide-MHC and soluble TCRs.
Diagnostic/prognostic biomarker/targets concept based on peptide over-presentation and gene over-expression.
Use with therapeutic indications across multiple cancer types, with emphasis on pancreatic cancer.
Interested in licensing this patent?